Clinical reference Biomarker Directory
Back to directory

C9

Established

C9 completes the membrane attack complex; deficiency causes a generally milder Neisseria susceptibility pattern.

Also known as Complement component 9
In plain language

C9 finishes building the complement system's bacteria-killing pore. Missing it tends to be a bit milder than missing the other terminal pieces, but it still raises the risk of Neisseria infections.

Biomarker & context

C9 is the final component of the membrane attack complex, polymerizing to complete the pore that lyses target bacterial cells at the end of the complement terminal pathway.

What it indicates

C9 deficiency is generally the mildest of the terminal complement deficiencies clinically, since partial MAC formation without C9 can still cause some bacterial lysis; nonetheless it is still associated with increased Neisseria infection susceptibility, particularly reported in some Japanese cohorts where C9 deficiency prevalence is notably higher.

Diagnosis & clinical testing

Identified through CH50/AH50 screening and specific terminal complement testing; often discovered incidentally or after an episode of meningococcal disease.

Guiding treatment

Meningococcal vaccination remains the key preventive measure; because C9 deficiency may be less clinically severe than other terminal defects, management is otherwise similar to standard care with attentive infection monitoring.

Clinical significance

Notably more prevalent in some Asian populations; part of the shared terminal complement deficiency group.

References
  1. ScienceDirect Topics. Complement Deficiency — an overview.